Raw Apatinib (811803-05-1) HPLC≥98% | AASraw selective inhibitor
MUTSVENE unoburitsa Cannabidiol (CBD) upfu uye Hemp Yakakosha Oiri muhuwandu!

Apatinib (811803-05-1)

Rating: SKU: 811803-05-1. Category:

MUTSVENE unobatsira nekugadzira zvigadzirwa kubva ku gram kusvika kuhutano hweApatinib (CAS 811803-05-1), pasi peCGMP mutemo uye nehutsika hwehutano hwehutano hwehutano.

Apatinib, nhamba duku duku inonzi tyrosine kinase inhibitor inhibits vascular endothelial kukura factor receptor-2, yakagamuchirwa kuti iite masastatic adenocarcinoma muChina muna Oct 2014. Uyu ndiwo mushumo wekutanga pamusoro pemashandisirwo ayo ekurasira yakakosha yekenza sechirongwa chetatu-line remitambo kusvika nhasi.   

AASRAW powder PDF Icon

Product Description

 

Apatinib video

 

 


 

Apatinib basic Characters

 

Name: Apatinib
CAS: 811803-05-1
Molecular Formula: C24H23N5O
Molecular Kurema: 397.47232
Melt Point: 111-114 ° C
Storage Temp: -20 ° C
Color: Pale Yellow to Yellow Solid

 


 

Apatinib (811803-05-1) kushandiswa mu steroid cycle

 

Mazita

Apatinib (CAS 811803-05-1), inozivikanwawo seYN968D1, Mesylate.

 

Apatinib Usage

Kanzera varwere vakashandiswa zvakasiyana-siyana zveApatinib zuva rezuva re28. Apatinib yakanga yakanyatsoraramika pamadhora pasi pe 750 mg / zuva, 3 ye3 murairo wekuregererwa kwezvinokonzera yakataurwa pa 1000 mg / zuva uye chiyero chakanyanya kubvumira chinotsanangurwa kuvaXXUMUM mg mgomo.

 

Warning on Apatinib

Iwe unofanirwa kuziva migumisiro kana iwe uchitora Apatinib. Maitiro akafanana eepatinib aiva hypertension uye hand-foot syndrome; zvisinei, kutyisa kwepatinib kwaive kudzora uye kunonzwisisika.

 

Mamwe mirayiridzo

Rivoceranib (Apatinib, YN968D1) ishoko rinoshandiswa pamuromo rinoshandiswa mumutauro weChina neLSK BioPharma, pakurapa zvirwere zvakasimba zvinosanganisira chirwere chepamusoro kana chemastatic gastric cancer, colorectal cancer, uye hepatocellular carcinoma. YN968D1 yakatanga kuumbwa uye yakabvumirwa neAdvenchen Laboratories mu Southern Southern California. Apatinib ikozvino inotengeswa muChina nokuda kwekenza yepamusoro yegastric neChina-yerinesi-chikwama-holder, Jiangsu Hengrui MedicineCo., Ltd iri pasi pezita rinonzi Aitan®. LSK BioPharma inobata kodzero dzenyika yose (kusina China) uye dzakabatanidzwa mukufambisa nekushambadzira kwe rivoceranibin South Korea.

Rivoceranib inoshandiswa zvikuru inhibitor yevascular endothelial kukurira factor receptor-2 (inozivikanwa seVEGFR2) iyo inopindirana nenzira yekutanga ye tumor-mediatedangiogenesis. Yakave yakaongororwa muhutano kune vanodarika 1,000 munyika yose uye yakagadziriswa kubudirira mune dzakawanda zvekenza zvinosanganisira kenza yegastric, karaireal cancer, hepatocellular carcinoma, isina kamudiki kemukirini yemapapu emapapu, kenza yesophageal, thyroidcancer, mesothelioma, uye neuroendocrine matumbo. Yakaratidzawo zvingave zvisingakwanisi kuvandudza migumisiro inosanganiswa nemakemikarirapeutics uye immunotherapy, pamwe chete nekuchengetedza chirwere.

 


 

Kutenga sei Apatinib kubva kuAASRAW

 

1.Kutaurirana nesu ne email yedu yekubvunza system, kana online skypeMutariri wevashandi (CSR).
2.Kutipa isu yakabvunzwa nekero.
3.Our CSR ichakupa iyo quotation, nguva yekubhadhara, nhamba yekutsvaga, nzira yekuendesa uye inofungidzirwa zuva rekuuya (ETA).
4.Payment yakaitwa uye zvigadzirwa zvichaendeswa mumaawa e12 (Kurongeka mukati me10kg).
5.Goods inogamuchira uye inopa mhinduro.